Unique Wealth Strategies LLC Purchases Shares of 626 Johnson & Johnson (NYSE:JNJ)

Unique Wealth Strategies LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 626 shares of the company’s stock, valued at approximately $99,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Tennessee Valley Asset Management Partners lifted its holdings in Johnson & Johnson by 3.1% in the 4th quarter. Tennessee Valley Asset Management Partners now owns 2,666 shares of the company’s stock worth $418,000 after buying an additional 80 shares during the period. River Road Asset Management LLC bought a new position in Johnson & Johnson in the 4th quarter worth $6,093,000. Daiwa Securities Group Inc. lifted its position in shares of Johnson & Johnson by 5.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 297,850 shares of the company’s stock worth $46,685,000 after purchasing an additional 15,490 shares during the period. Livforsakringsbolaget Skandia Omsesidigt boosted its stake in shares of Johnson & Johnson by 2.4% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 98,882 shares of the company’s stock valued at $15,499,000 after purchasing an additional 2,345 shares in the last quarter. Finally, Peterson Wealth Services raised its stake in Johnson & Johnson by 9.7% in the fourth quarter. Peterson Wealth Services now owns 25,773 shares of the company’s stock worth $4,040,000 after buying an additional 2,285 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several research reports. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. The Goldman Sachs Group decreased their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Sanford C. Bernstein boosted their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, August 5th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Friday, August 16th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Price Performance

Shares of JNJ opened at $164.10 on Friday. The firm has a 50 day moving average of $153.92 and a 200 day moving average of $153.27. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $167.78. The company has a market capitalization of $394.94 billion, a P/E ratio of 10.23, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter in the previous year, the business earned $2.80 earnings per share. The company’s revenue was up 4.3% on a year-over-year basis. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.